Anti-PD-1 antibodies have been applied for diverse solid tumors, achieving objective and robust responses with an acceptable safety profile. PD-L1 is commonly expressed by malignant cells and can interact with PD-1 on T cells to prevent an effective antitumor immune response in the tumor microenvironment. Once PD-1 is engaged by one of these two ligands, it inhibits kinase signaling, which typically leads to T cell activation, thereby suppressing T cell function. PD-1 primarily mediates immunosuppression in peripheral tissues by interacting with PD-1 ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed by tumor cells and/or stromal cells. PD-1 is a key immune-checkpoint receptor that is rapidly expressed after T cell activation. Among them, the targeting of checkpoint inhibitors, such as programmed death 1 (PD-1) inhibitor, appears to be a promising treatment strategy. Fortunately, several new classes of molecularly targeted agents with better efficacy and less toxicity have been developed in recent decades however, these novel agents have varying degrees of efficacy for different types of lymphoma. Even in Hodgkin’s lymphoma (HL), one of the first cancers to be cured, a combination of chemotherapy and radiotherapy can result in long-term toxicities and thus negatively impact the quality of life of patients. Prior to the mid-1990s, treatment for lymphoma relied on combination cytotoxic chemotherapy, which kills rapidly dividing cells but exposes patients to toxic effects, such as myelosuppression, alopecia, and mucositis. Nonetheless, recent advances in molecular genetics have vastly improved our understanding of the biological diversity of this disease and have led to the discovery of novel therapies. Indeed, lymphoma accounts for 3–5% of all cancer diagnoses, with approximately 452,000 new cases and 225,000 deaths per year worldwide. According to GLOBOCAN estimates for 2012, the incidence of lymphoma is rising. Lymphomas are malignancies of lymphocytes involving malignant cells that are arrested at different stages of differentiation in lymph nodes, bone marrow, and other tissues.

Moreover, treatment with approved PD-1 inhibitors was well tolerated. The pooled incidence of treatment-related all-grade AEs and grade-3/4 AEs was 0.84 (95% CI: 0.75–0.92) and 0.21 (95% CI: 0.15–0.29), respectively.Ĭonclusion: Patients with PD-L1 overexpression in relapsed or refractory lymphoma benefited more from anti-PD-1 therapy. According to PD-L1 expression subgroup analysis, the PD-L1-positive group exhibited significantly better outcomes than the PD-L1-negative group (Z=5.481, p=0.000), with pooled ORRs of 0.74 (95% CI: 0.67–0.81) and 0.2 (95% CI: 0.11–0.3), respectively. There was evidence of significant heterogeneity among the studies. Results: Thirteen articles were selected, and 9 studies were included in the meta-analysis. Heterogeneity across studies was analyzed using Q and I 2 statistics. Data were analyzed using a random-effects meta-analysis to determine risk ratios. The pooled overall response rate (ORR), progression-free survival (PFS), complete remission rate (CRR), overall survival (OS) and adverse events (AEs) were calculated and compared. Methods: A quantitative meta-analysis was performed via a systematic search in PubMed, Web of Science, and The Cochrane Library. We conducted this meta-analysis to explore subtypes benefiting from this treatment and the best anti-PD1 therapeutic modalities. Received: OctoAccepted: JPublished: October 19, 2018Īnti-PD1 antibodies exhibit satisfactory efficacy in treating certain types of lymphoma. ChinaĬong Ye, email: Zhou, email: Anti-PD1 antibodies lymphoma clinical activity safety meta-analysis ChinaĢDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. Zhe Geng 1, Yi Xiao 1, Xiao-Jian Zhu 1, Cong Ye 2 and Jian-Feng Zhou 1ġDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.

Oncotarget endnote free